CIP2A overexpression is associated with c-Myc expression in colorectal cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To improve the prognostic evaluation of colorectal cancer requires new molecular markers. Cancerous inhibitor of protein phosphatase 2A (CIP2A) serves as an oncoprotein by targeting PP 2A-mediated inhibition of c-Myc. A prognostic role for CIP2A has been demonstrated in gastric, lung and tongue cancers. RESULTS: CIP2A was overexpressed in 661 (87.9%) specimens. CIP2A overexpression was associated with tumor differentiation grade (p = 0.014), p53 immunopositivity (p = 0.042), EGFR immunopositivity (p = 0.007) and c-Myc nuclear immunopositivity (p = 0.018). In survival analysis, CIP2A failed to show any prognostic significance (p = 0.270, log-rank test). METHODS: 863 consecutive colorectal cancer patients treated at Helsinki University Central Hospital in 1983–2001 were collected with 752 scored successfully for CIP2A immunohistochemical expression from tumor tissue microarrays. Associations with clinicopathologic variables and molecular markers were explored by the chi-square test, and the Kaplan-Meier method served for survival analysis. CONCLUSIONS: Overexpression of CIP2A in colorectal cancer patients may be an important step in colorectal carcinogenesis. Based on our findings, CIP2A shows no association with patient prognosis in colorectal cancer, but is associated with nuclear c-Myc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 3×
“dephosphorylation of c-Myc.(6) Overexpression of CIP2A is evident in acute myeloid leukemia, in epithelial carcinomas, and in adenocarcinomas;(6-11) though little is known of its possible role in human cancers.”
BackgroundInfluentialCIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221
Hoo, L. S., Zhang, J. Y., & Chan, E. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205625 · Cited by 201
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · cited 6×
“A prognostic role for CIP2A has been demonstrated in certain subgroups of gastric cancer.(12) In lung cancer, CIP2A is an independent prognostic marker,(13) but in colorectal cancer its impact on prognosis remains unknown.”
BackgroundMethodResultSelf-citationPrognostic role of CIP2A expression in serous ovarian cancer
Böckelman, C., Lassus, H., Hemmes, A., Leminen, A., Westermarck, J., Haglund, C., Bützow, R., & Ristimäki, A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.346 · Cited by 100 · cited 1×
“Though we failed to show a prognostic value for CIP2A, the strengths of this study are a large, well-characterized colorectal cancer patient cohort with a long follow-up time, and a standard protocol for evaluating CIP2A immunoreactivity.(12,14,15) The test series included over 550 patients and the validation series o…”
ResultSelf-citation
Cited by
Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers
Khanna, A., & Pimanda, J. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.29431 · Cited by 57
Kaipio, K., Chen, P., Roering, P., Huhtinen, K., Mikkonen, P., Östling, P., Lehtinen, L., Mansuri, N., Korpela, T., Potdar, S., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5356 · Cited by 54
CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis
Fang, Y., Li, Z., Wang, X., & Zhang, S. (2012) · Tumor Biology · doi:10.1007/s13277-012-0492-2 · Cited by 40
Metadata
- Authors
- Böckelman, C., Koskensalo, S., Hagström, J., Lundin, M., Ristimäki, A., & Haglund, C.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2012-03
- Volume
- 13
- Issue
- 5
- Pages
- 289-295
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2016594516
- Cited by
- 65
- References
- 5
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.